FDA
-
-
-
-
-
-
-
NovoCure Ltd. (NVCR) PT Raised to $47 at H.C. Wainwright
-
-
-
-
-
-
-
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on NovoCure Ltd. (NVCR)
-
-
-
-
-
-
-
Novocure (NVCR): FDA Approves Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
-
-
-
-
-
-
-
Novocure (NVCR): FDA Approves Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
Novocure Reports Second Quarter 2023 Financial Results
-
334,268 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


